Loading data for NGNE — first visit, this takes a few seconds.
Neurogene Inc.
24.17 +0.92 (3.96%)
- Market Cap
- $483.7M
- Volume
- 240K
- Dividend yield
- 0.00%
- Next earnings date
- Aug 11, 2026
Neurogene Inc. (NGNE) Stock Price, Analysis & Data
Intrinsic value
See plans →Analyst Forecast
Stock Forecasts →$46.00 – $166.00
Median $65.00 · 168.93% upside
You're seeing the free overview
Create a free account to explore more research on this ticker.
Latest Earnings
| Reported | Vs estimate | YoY Change | |
|---|---|---|---|
| Revenue | $0 | n/a | n/a |
| EPS | -$1.13 | +$0.11 | -14.14% |
Metrics
- Bid
- 25.99
- Market Cap
- 484M
- Revenue (ttm)
- n/a
- Net Income (ttm)
- -111M
- 2.09
- -5.04
- n/a
- -4.22
- P/B (ttm)
- 1.76
- P/S (ttm)
- n/a
- Earnings Date
- Aug 11, 2026
- Ask
- 44.63
- Volume
- 240,155
- Avg. Volume (20D)
- 270,050
- Open
- 23.26
- Previous Close
- 23.25
- Day's Range
- 22.78 - 24.39
- 52-Week Range
- 15.93 - 43.66
- Analyst
- Strong Buy
- Price Target
- 65 (168.93%)
- Dividends
- n/a
- Ex-Dividend Date
- n/a
About Neurogene Inc.
View profile →Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Industry Biotechnology
Sector Healthcare
IPO Date Mar 7, 2014
Employees 131
Stock Exchange NasdaqGM
Ticker Symbol NGNE
Website https://www.neurogene.com